Can-Fite BioPharma Ltd. CANF
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | -43.30% | -43.30% | -36.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | -43.30% | -43.30% | -36.08% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | -43.30% | -43.30% | -36.08% |
| SG&A Expenses | -30.98% | -30.98% | 4.86% | 4.86% | 35.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.27% | -4.27% | 19.59% | 19.59% | 15.65% |
| Operating Income | 4.45% | 4.45% | -25.17% | -25.17% | -19.64% |
| Income Before Tax | 5.64% | 5.64% | -26.23% | -26.23% | -23.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.64% | 5.64% | -26.23% | -26.23% | -23.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.64% | 5.64% | -26.23% | -26.23% | -23.22% |
| EBIT | 4.45% | 4.45% | -25.17% | -25.17% | -19.64% |
| EBITDA | 4.02% | 4.02% | -25.33% | -25.33% | -19.11% |
| EPS Basic | 71.08% | 71.08% | 50.59% | 50.59% | 34.22% |
| Normalized Basic EPS | 71.09% | 71.09% | 50.46% | 50.46% | 34.22% |
| EPS Diluted | 71.08% | 71.08% | 50.59% | 50.59% | 34.22% |
| Normalized Diluted EPS | 71.09% | 71.09% | 50.46% | 50.46% | 34.22% |
| Average Basic Shares Outstanding | 226.30% | 226.30% | 155.49% | 155.49% | 87.33% |
| Average Diluted Shares Outstanding | 226.30% | 226.30% | 155.49% | 155.49% | 87.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |